Invivyd (IVVD) Consolidated Net Income (2021 - 2025)
Invivyd (IVVD) posted Consolidated Net Income of -$12.2 million for Q4 2025, down 3.33% on a QoQ basis from -$11.8 million in Q3 2025, and up 33.93% year-over-year from -$9.1 million in Q4 2024.
Invivyd (IVVD) Consolidated Net Income (2021 - 2025) Analysis & Trends
Invivyd's Consolidated Net Income history runs 5 years deep, the most recent figure standing at -$12.2 million for Q4 2025.
- Quarterly Consolidated Net Income rose 33.93% year-over-year to -$12.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$56.6 million (up 73.07% YoY) and the FY2025 annual result came in at -$307.8 million, up 26.95% from the prior year.
- Consolidated Net Income was -$12.2 million for Q4 2025 at Invivyd, down from -$11.8 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$11.8 million in Q3 2025 and bottomed at -$647.2 million in Q3 2021.
- A 5-year average of -$82.3 million and a median of -$51.6 million in 2022 frame the typical range for Consolidated Net Income.
- Peak annual rise in Consolidated Net Income reached 91.74% in 2022, while the deepest fall reached 186.87% in 2022.
- Invivyd's Consolidated Net Income stood at -$83.3 million in 2021, then soared by 41.88% to -$48.4 million in 2022, then tumbled by 57.51% to -$76.3 million in 2023, then jumped by 75.71% to -$18.5 million in 2024, then soared by 33.93% to -$12.2 million in 2025.
- Business Quant data shows IVVD's Consolidated Net Income at -$12.2 million in Q4 2025, -$11.8 million in Q3 2025, and -$15.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Invivyd | 105.10 Mn | -121.59 Mn | 16.07 Mn | -12.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.24 Mn |
| Sep 30, 2025 | -11.85 Mn |
| Jun 30, 2025 | -15.42 Mn |
| Mar 31, 2025 | -17.12 Mn |
| Dec 31, 2024 | -18.53 Mn |
| Sep 30, 2024 | -62.75 Mn |
| Jun 30, 2024 | -49.68 Mn |
| Mar 31, 2024 | -79.34 Mn |
| Dec 31, 2023 | -76.26 Mn |
| Sep 30, 2023 | -45.04 Mn |
| Jun 30, 2023 | -54.31 Mn |
| Mar 31, 2023 | -39.78 Mn |
| Dec 31, 2022 | -48.41 Mn |
| Sep 30, 2022 | -53.46 Mn |
| Jun 30, 2022 | -58.72 Mn |
| Mar 31, 2022 | -111.33 Mn |
| Dec 31, 2021 | -83.29 Mn |
| Sep 30, 2021 | -647.18 Mn |
| Jun 30, 2021 | -122.23 Mn |
| Mar 31, 2021 | -38.81 Mn |